H
Hiroaki Shimokawa
Researcher at Tohoku University
Publications - 976
Citations - 56856
Hiroaki Shimokawa is an academic researcher from Tohoku University. The author has contributed to research in topics: Heart failure & Endothelium. The author has an hindex of 111, co-authored 949 publications receiving 48822 citations. Previous affiliations of Hiroaki Shimokawa include University of Nebraska Medical Center & Nagoya University.
Papers
More filters
Journal ArticleDOI
Potential usefulness of fish oil in the primary prevention of acute coronary syndrome.
Satoshi Yasuda,Hiroaki Shimokawa +1 more
TL;DR: Vulnerable plaques that are likely to rupture or erode have evidence of inflammation, together with thin fibrous caps and large lipid cores, and the platelet-rich thrombus, developed in association with pro-coagulant-vulnerable blood, can release vasoconstrictor substances such as serotonin and thromboxane A2 that may induce vasoconSTriction at the site of plaque rupture or in the …
Journal ArticleDOI
Retraction. Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy: sub-analysis of the KYOTO HEART study.
Journal ArticleDOI
Beating myocardium counteracts myogenic tone of coronary microvessels: involvement of ATP-sensitive potassium channels
Satoru Takeda,Tatsuya Komaru,Katsuaki Takahashi,Kouichi Sato,Hiroshi Kanatsuka,Yasunori Kokusho,Kunio Shirato,Hiroaki Shimokawa +7 more
TL;DR: It is concluded that the beating myocardium counteracts myogenic tone by releasing transferable vaso active signals that affect the endothelium and the vascular smooth muscle, and that the signals are solely mediated by the activation of K(ATP) channels, unlike the rapid pacing-induced vasoactive factors.
Book ChapterDOI
Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
TL;DR: Clinical value of combination therapy with RAAS inhibitors and β-blocker is not well established in HF with preserved EF (HFpEF), and the heterogeneity of diagnostic criteria and baseline characteristics of HFpEF need further evidence for the combination therapy.
Journal ArticleDOI
Pathophysiology and Diagnosis of Coronary Functional Abnormalities.
TL;DR: In this article, the authors briefly summarise the recent advances in the understanding of pathophysiology and diagnosis of epicardial coronary artery spasm and coronary microvascular dysfunction.